Spesolimab (spesolimab-sbzo; SPEVIGO®) is an interleukin (IL)-36 receptor antagonist
being developed by Boehringer Ingelheim for the treatment of various immune-mediated …

Introduction Generalized pustular psoriasis (GPP) is a rare, severe, clinically heterogeneous
disease characterized by flares of widespread, noninfectious, macroscopically visible …

Background Spesolimab is an anti-interleukin-36 receptor monoclonal antibody approved to
treat generalised pustular psoriasis (GPP) flares. We aimed to assess the efficacy and safety …

Importance Generalized pustular psoriasis (GPP) lacks internationally accepted definitions
and diagnostic criteria, impeding timely diagnosis and treatment and hindering cross …

Generalized pustular psoriasis (GPP) is a rare subset of psoriasis involving episodes of
sterile pustules accompanied by inflammation and, often, systemic involvement. The …

Generalized pustular psoriasis (GPP) is a rare, chronic, and severe inflammatory skin
disorder characterized by sudden eruption of sterile pustules, often accompanied by …

Generalized pustular psoriasis (GPP) is a rare, chronic, inflammatory skin disorder
characterized by recurrent flares associated with skin erythema, desquamation, and …

Generalized pustular psoriasis (GPP) is a severe and rare form of psoriasis, being a
potentially life-threatening condition, characterized by recurring episodes or flares of …

Psoriasis is a chronic inflammatory skin disease characterized by the appearance of clearly
demarcated erythematous and scaly plaques. It can be divided into various types, including …

Acute generalized exanthematous pustulosis (AGEP) is a rare, acute, severe cutaneous
adverse reaction mainly attributed to drugs, although other triggers, including infections …